PMLiVE19h
Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA
Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...
Retinal diseases: RNA therapeutics show promise but is India ready?
Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...
Le Lézard18h
Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition
Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein ...
Le Lézard18h
Princeton Biopartners Welcomes Dr. Synøve Kamøy as Engagement Manager
Princeton Biopartners, a best-in-class provider of integrated consulting solutions to the life sciences sector, proudly announces the appointment of Synøve Kamøy, M.D., as Engagement Manager. This ...
F. Hoffmann-La Roche Ltd: Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
Group sales grew by 7%1 at constant exchange rates (CER; 3% in CHF), driven by strong demand for both medicines and diagnostics.Excluding COVID-19, Group sales increased by 9%.
SMA17h
Levodopa therapy could ease SMA symptoms, per new mouse study
Problems with chemical messengers like dopamine were tied to posture issues in SMA in a mouse study, but levodopa therapy may ease symptoms.